The American College of Physicians (ACP) issued new A1C guidelines for people managing type 2 diabetes, drawing both criticism and praise. Here’s what to know about the new target range and what ...

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

In this study, we demonstrate a case series of three patients with a substantial reduction in A1C and significantly reducing the need for pharmacotherapy without clinically significant weight loss.

A, hazard ratios for the risk of acute myocardial infarction in type 2 diabetes mellitus by body mass index and hemoglobin A1c vs age‐ and sex‐matched population comparators (reference), among men ...

Mifepristone reduced A1C by 1.5% as compared to a reduction of 0.2% with placebo. The A1C reductions occurred even as many patients decreased or stopped other diabetes medications, including insulin.

Mifepristone reduced A1C by 1.5% as compared to a reduction of 0.2% with placebo. The A1C reductions occurred even as many patients decreased or stopped other diabetes medications, including insulin.

In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin.

In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. The complete results from these studies were presented at the American ...

Once-weekly insulin helped patients achieve an average A1C of 6.92% in QWINT-1 trial Results support once-weekly insulin as effective alternative to daily treatment CHICAGO, June 22, 2025 /PRNewswire/ ...

Impairment of wound healing and blood flow in diabetes, a serious complication of types 1 and 2 diabetes, is associated with delayed muscle regeneration, atrophy, and, in severe cases, limb amputation ...